Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 207 for “"DLBCL"”.
-
Κυτταρική θεραπεία με CAR T σε ασθενείς με λέμφωμα DLBCL (Μεγαλοκυτταρικό B-λέμφωμα)
… μεγάλα Β-κύτταρα (Diffuse Large B-cell Lymphoma, DLBCL) περιλαμβάνει μία ετερογενή ομάδα μορφολογικά, γενετικά, και κλινικά διακριτών ασθενειών. Εμφανίζεται κυρίως σε άτομα μεγαλύτερα των 60 ετών, παρόλα αυτά μπορεί να εμφανιστεί και σε παιδιά και εφήβους. Η αιτιολογία της νόσησης από DLBCL …
-
Funktionelle Validierung von Onkogenen bei molekularen Subtypen von diffusen großzelligen B-Zell Lymphomen (DLBCL)
Das diffuse großzellige B-Zell Lymphom (DLBCL) stellt mit einem Anteil von ca. 30-40% den häufigsten Lymphom-Subtyp bei Erwachsenen dar. Es ist eine heterogene diagnostische Kategorie, die anhand von Genexpressionsanalysen in zwei vorherrschende molekulare Subtypen unterteilt werden kann: Den …
-
Inhibition of Fatty Acid Amide Hydrolase Increases Rates of Apoptosis in Cell Line Models of DLBCL and Breast Cancer
… cancers with high heterogeneity such as DLBCL and breast cancer remain difficult to treat, with many patients having few treatment options. The endocannabinoid system has been identified as a potential wellspring of therapeutic agents that can potentially increase cell death and prevent …
-
Unraveling the Underlying Mechanism of Bcl-2 Mutations Regulated Apoptotic Blocks in Diffuse Large B-Cell Lymphoma (Dlbcl) Patients
… data obtained from a large series of DLBCLs have identified frequent mutations in the translocated BCL2 gene. However, the heterogeneity of the mutation profile complicates the prediction of the functional effects of the DLBCL-specific mutations. The aim of the research is to present …
-
Characterizing Therapy Induced Polyploidy (TIP) Populations as a Resistance Mechanism in DH/DE-DLBCL and Identifying Synthetic Lethal Targeted Therapies
… cancer in USA. Diffuse large B-cell lymphoma (DLBCL) and Peripheral T-cell lymphoma (PTCL) are the most common types of aggressive B-cell and T-cell non-Hodgkin lymphomas (NHL) respectively. Double-Hit or Double-Expresser DH/DE-DLBCL are high grade B-cell lymphomas characterized by …
-
Elucidation of the Mechanisms of Resistance and Sensitivity to Histone Deacetylase Inhibitor, PXD101, in Diffuse Large B-Cell Lymphoma (DLBCL)
… of cases, Diffuse Large B-cell Lymphoma (DLBCL), the most prevalent Non-Hodgkin Lymphoma (NHL) throughout the world, is still fatal for 30-40% patients. This patient population could benefit from the addition of new drugs to the current DLBCL chemotherapy regimen. Histone deacetylase …
-
Genetische Charakterisierung diffuser großzelliger B-Zell Lymphome vom Keimzentrumstyp, vom aktivierten B-Zelltyp und von primär mediastinalen diffusen großzelligen B-Zell Lymphomen
Diffuse großzellige B-Zell Lymphome (DLBCL) gehören zu den häufigsten lymphatischen Tumoren. Die histologische Klassifikation dieser großen Gruppe von Tumoren ist dabei noch immer durch die mangelnde Reproduzierbarkeit in der Diagnostik geprägt. Außerdem verhalten sich DLBCL klinisch ausgesprochen …
-
Διερεύνηση των μοριακών μηχανισμών του Μεταγωγέα Σήματος και Ενεργοποιητή της Μεταγραφής 3 (STAT3) στο Διάχυτο Λέμφωμα από Μεγάλα Β Κύτταρα
… μεγάλα Β-κύτταρα (Diffuse Large B Cell Lymphoma, DLBCL) αποτελεί τον πλέον διαδεδομένο τύπο λεμφώματος μη Hodgkin, και παρουσιάζει μεγάλη ετερογένεια στη νόσο ως προς τις θέσεις εμφάνισης του όγκου, τα μοριακά χαρακτηριστικά και την κλινική συμπτωματολογία. Το DLBCL μπορεί να διαχωριστεί σε δύο …
-
The Impact of Diffuse Large B-Cell Lymphoma on Primary Care and Costs of Chronic Conditions in Elderly Medicare Beneficiaries
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of Non-Hodgkin's lymphoma with a median age of diagnosis of 67 years. The intensive treatment of DLBCL can negatively influence elderly patients' preventive and chronic care, which can increase the costs of different chronic conditions. …
-
Die Rolle des Tumorsuppressors PTEN bei der molekularen Pathogenese diffuser großzelliger B-Zell-Lymphome
Diffuse großzellige B-Zell-Lymphome (DLBCL) repräsentieren den häufigsten Subtyp maligner Lymphome. Sie stellen bezüglich ihrer Morphologie, Biologie, und ihres klinischen Verlaufes eine sehr heterogene Gruppe von Erkrankungen dar. Durch genomweite Genexpressionsstudien konnten zwei vorherrschende …
-
The hematopoietic oncoprotein FOXP1 promotes cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non- Hodgkin lymphoma. With current treatment regimens, a substantial part of DLBCL patients can be cured. However, up to 40% will not achieve durable remissions and eventually will succumb to recurrent disease. Using gene expression …
-
Biomarker identification in HIV and non-HIV related lymphomas
DLBCL is the most common lymphoma subtype occurring in older populations as well as in younger HIV infected patients. The current treatment options for DLBCL are effective for most patients yet the relapse rate is high. While many biomarkers for DLBCL exist, they are not in clinical use due to low …
-
Die Rolle von NFATc1 bei der molekularen Pathogenese von diffusen großzelligen B-Zell-Lymphomen
Diffuse großzellige B-Zell-Lymphome (DLBCL) sind aggressive Neoplasien reifer B-Zellen und repräsentieren die häufigsten neu diagnostizierten Lymphome. Genexpressionsanalysen gelang die Differenzierung der heterogenen DLBCL in mindestens zwei vorherrschende molekulare Subtypen, mit einem …
-
Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease. Identification of prognostic and predictive markers is important to design individualised and effective treatment strategies. This thesis describes different approaches to search for molecular prognostic markers and …
-
TARGETING DNA DAMAGE RESPONSE KINASES TO IMPROVE CHEMOTHERAPY EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA
Diffuse large B cell lymphoma (DLBCL) is the most common form of Non-Hodgkin’s Lymphoma, and about half of the patients relapse or are refractory to first line treatment, R-CHOP—an immunochemotherapy consisting of Rituximab and chemotherapy agents. Targeting the DNA Damage Response (DDR) pathway …
-
Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation
Diffuse Large B cell Lymphoma (DLBCL) is an aggressive disease that displays striking heterogeneity at both the molecular and clinical levels; and as a result, up to 40% of patients relapse or are refractory to standard first-line therapy. DLBCL is the most common subtype of lymphoma affecting …
-
The role of sphingosine-1-phosphate on macrophage recruitment and function in diffuse large B-cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Currently, approximately 40% of DLBCL patients treated with standard of care therapies, which include a combination of immunotherapy (Rituximab; R) and chemotherapy (CHOP), will have disease that is refractory or will …
Page 1 of 11